Nana Sasaki

Kyoto, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Alemtuzumab-based HLA-haploidentical transplantation for relapsed/refractory aggressive NK-cell leukemia

Alemtuzumab-based HLA-haploidentical transplantation for relapsed/refractory aggressive NK-cell leukemia

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: May 13, 2026

Non-infectious fever defines a subgroup of patients with poorer survival outcomes in high-risk myelodysplastic syndrome.

Non-infectious fever defines a subgroup of patients with poorer survival outcomes in high-risk myelodysplastic syndrome.

Journal: British journal of haematology

Published: February 02, 2026

Lead poisoning diagnosed in a patient with anemia accompanied by abdominal pain

Lead poisoning diagnosed in a patient with anemia accompanied by abdominal pain

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: November 05, 2025

Real-world data of polatuzumab vedotin with bendamustine and rituximab for Japanese relapsed and refractory DLBCL: a multicenter retrospective study.

Real-world data of polatuzumab vedotin with bendamustine and rituximab for Japanese relapsed and refractory DLBCL: a multicenter retrospective study.

Journal: Leukemia & lymphoma

Published: March 26, 2025

Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML.

Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML.

Journal: Leukemia

Published: December 09, 2024

Editor's Note: Targeting Activating Transcription Factor 3 by Galectin-9 Induces Apoptosis and Overcomes Various Types of Treatment Resistance in Chronic Myelogenous Leukemia.

Editor's Note: Targeting Activating Transcription Factor 3 by Galectin-9 Induces Apoptosis and Overcomes Various Types of Treatment Resistance in Chronic Myelogenous Leukemia.

Journal: Molecular cancer research : MCR

Published: June 04, 2024

Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma.

Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma.

Journal: Leukemia & lymphoma

Published: February 11, 2022

Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study.

Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study.

Journal: International journal of hematology

Published: October 01, 2021

Durable Remission of Chemotherapy-Refractory Myeloid Sarcoma by Azacitidine.

Durable Remission of Chemotherapy-Refractory Myeloid Sarcoma by Azacitidine.

Journal: The Tohoku journal of experimental medicine

Published: June 21, 2021

Detection of novel and recurrent conjoined genes in non-Hodgkin B-cell lymphoma.

Detection of novel and recurrent conjoined genes in non-Hodgkin B-cell lymphoma.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: April 22, 2021

Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients.

Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients.

Journal: Cancer reports (Hoboken, N.J.)

Published: February 21, 2021

Paroxysmal nocturnal hemoglobinuria complicated with essential thrombocythemia harboring concomitant PIGA, CALR, and ASXL1 mutations.

Paroxysmal nocturnal hemoglobinuria complicated with essential thrombocythemia harboring concomitant PIGA, CALR, and ASXL1 mutations.

Journal: Annals of hematology

Published: September 25, 2020

Showing 1-12 of 22

Last Updated: 09/26/2026